Allergy Therapeutics
Market Cap
UK£74.7m
Last Updated
2019/10/20 20:33 UTC
Data Sources
Company Financials +
Executive Summary
Allergy Therapeutics plc engages in the research and development of allergy treatments.
Snowflake
Fundamentals
Excellent balance sheet and overvalued.
Share Price & News
How has Allergy Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.3%
AGY
-1.6%
GB Pharmaceuticals
-0.4%
GB Market
1 Year Return
-33.2%
AGY
11.7%
GB Pharmaceuticals
2.9%
GB Market
Return vs Industry: AGY underperformed the UK Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: AGY underperformed the UK Market which returned 2.9% over the past year.
Shareholder returns
| AGY | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.3% | -1.6% | -0.4% |
| 30 Day | -7.8% | -5.3% | -1.4% |
| 90 Day | 0% | 5.4% | -2.1% |
| 1 Year | -33.2%-33.2% | 15.1%11.7% | 8.0%2.9% |
| 3 Year | -52.0%-52.0% | 44.2%30.1% | 18.0%3.6% |
| 5 Year | -37.3%-37.3% | 83.8%53.5% | 35.8%6.4% |
Price Volatility Vs. Market
How volatile is Allergy Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Allergy Therapeutics plc's (LON:AGY) 9.2% ROE Better Than Average?4 weeks ago | Simply Wall St
If You Had Bought Allergy Therapeutics (LON:AGY) Stock Five Years Ago, You'd Be Sitting On A 48% Loss, Today1 month ago | Simply Wall St
Health Check: How Prudently Does Allergy Therapeutics (LON:AGY) Use Debt?Valuation
Is Allergy Therapeutics undervalued compared to its fair value and its price relative to the market?
21.45x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AGY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AGY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AGY is poor value based on its PE Ratio (21.4x) compared to the Pharmaceuticals industry average (21.4x).
PE vs Market: AGY is poor value based on its PE Ratio (21.4x) compared to the UK market (16.8x).
Price to Earnings Growth Ratio
PEG Ratio: AGY's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: AGY is good value based on its PB Ratio (2x) compared to the GB Pharmaceuticals industry average (2.6x).
Next Steps
Future Growth
How is Allergy Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
-40.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGY's earnings are forecast to decline over the next 3 years (-40.8% per year).
Earnings vs Market: AGY's earnings are forecast to decline over the next 3 years (-40.8% per year).
High Growth Earnings: AGY's earnings are forecast to decline over the next 3 years.
Revenue vs Market: AGY's revenue (7.4% per year) is forecast to grow faster than the UK market (3.9% per year).
High Growth Revenue: AGY's revenue (7.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AGY is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Allergy Therapeutics performed over the past 5 years?
-8.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: AGY's earnings have declined by -8% per year over the past 5 years.
Accelerating Growth: AGY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AGY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.9%).
Return on Equity
High ROE: AGY's Return on Equity (9.2%) is considered low.
Return on Assets
ROA vs Industry: AGY's Return on Assets is below or equal to the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: AGY's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Allergy Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AGY's short term assets (£46.6M) exceeds its short term liabilities (£16.9M)
Long Term Liabilities: AGY's short term assets (46.6M) exceeds its long term liabilities (14.1M)
Debt to Equity History and Analysis
Debt Level: AGY's debt to equity ratio (6.5%) is considered satisfactory
Reducing Debt: AGY's debt to equity ratio has increased from 0.3% to 6.5% over the past 5 years.
Debt Coverage: AGY's debt is well covered by operating cash flow (229.9%).
Interest Coverage: AGY earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: AGY has a high level of physical assets or inventory.
Debt Coverage by Assets: AGY's debt is covered by short term assets (assets are 19.139980x debt).
Next Steps
Dividend
What is Allergy Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate AGY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AGY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if AGY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGY's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
Next Steps
Management
What is the CEO of Allergy Therapeutics's salary, the management and board of directors tenure and is there insider trading?
3.8yrs
Average management tenure
CEO
Manuel Llobet (55yo)
10.3yrs
Tenure
UK£555,870
Compensation
Mr. Manuel Llobet has been the Chief Executive Officer of Allergy Therapeutics plc since July, 2009. Mr. Llobet joined Allergy in September 2009 following the successful refinancing by Azure Ventures Limit ...
CEO Compensation Analysis
Compensation vs. Market: Manuel's total compensation ($USD715.53K) is about average for companies of similar size in the UK market ($USD320.52K).
Compensation vs Earnings: Manuel's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.8yrs
Average Tenure
Experienced Management: AGY's management team is considered experienced (3.8 years average tenure).
Board Age and Tenure
3.3yrs
Average Tenure
59.5yo
Average Age
Experienced Board: AGY's board of directors are considered experienced (3.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chairman of the Board Independent Chairman |
| Shares | 20,000 |
| Max Price | UK£0.18 |
| Entity | Individual |
| Role | Member of the Board of Directors CFO & Director |
| Shares | 150,000 |
| Max Price | UK£0.17 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Executive Director |
| Shares | 50,000 |
| Max Price | UK£0.17 |
Ownership Breakdown
Management Team
Bev Lees
Group Operations Director
- Tenure: 3.8yrs
Manuel Llobet (55yo)
CEO & Executive Director
- Tenure: 10.3yrs
- Compensation: UK£555.87k
Santi Puig
Business Development Director
- Tenure: 10yrs
Murray Skinner
Chief Scientific Officer
- Tenure: 3.8yrs
Sue Baker
Head of Human Resources
- Tenure: 0yrs
Russell Picket
Group Financial Controller
- Tenure: 0yrs
Nick Wykeman (54yo)
CFO & Director
- Tenure: 3.3yrs
- Compensation: UK£251.38k
Sara Goldsbrough
Company Secretary
- Tenure: 2.9yrs
Simon Piggott
Head of Clinical Science
- Tenure: 2.1yrs
Board Members
Tunde Otulana (62yo)
Independent Non-Executive Director
- Tenure: 2.3yrs
- Compensation: UK£40.00k
Peter Jensen (68yo)
Independent Chairman
- Tenure: 9yrs
- Compensation: UK£94.00k
Mary Tavener (57yo)
Non-Executive Director
- Tenure: 0.3yrs
Stephen Smith (65yo)
Senior Independent Director
- Tenure: 0yrs
- Compensation: UK£48.73k
Johannes Ring
Member of Scientific Advisory Board
- Tenure: 0yrs
Hendrik Nolte
Chairman of Scientific Advisory Board
- Tenure: 0yrs
Anthony Frew
Member of Scientific Advisory Board
- Tenure: 0yrs
Lawrence Du Buske
Member of Scientific Advisory Board
- Tenure: 0yrs
Manuel Llobet (55yo)
CEO & Executive Director
- Tenure: 10.3yrs
- Compensation: UK£555.87k
Nick Wykeman (54yo)
CFO & Director
- Tenure: 3.3yrs
- Compensation: UK£251.38k
Company Information
Allergy Therapeutics plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Allergy Therapeutics plc
- Ticker: AGY
- Exchange: AIM
- Founded: 1934
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£74.750m
- Shares outstanding: 636.17m
- Website: https://www.allergytherapeutics.com
Number of Employees
Location
- Allergy Therapeutics plc
- Dominion Way
- Worthing
- West Sussex
- BN14 8SA
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AGYT.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Oct 2004 |
| AGY | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Oct 2004 |
Biography
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of po ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/20 20:33 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.